Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway

Simple item page
dc.contributor.authorDirican, A
dc.contributor.authorAtmaca, H
dc.contributor.authorBozkurt, E
dc.contributor.authorErten, C
dc.contributor.authorKaraca, B
dc.contributor.authorUslu, R
dc.date.accessioned2024-07-18T12:05:03Z
dc.date.available2024-07-18T12:05:03Z
dc.description.abstractThe treatment of castrate-resistant prostate cancer (CRPC) still remains as an important challenge of daily oncology practice. Docetaxel significantly prolongs overall survival in men with CRPC. Thymoquinone (TQ), one of the flavonoid compounds isolated from Nigealla sativa, has been shown to possess cytotoxic activity against a variety of cancer cell lines. The aim of the study was to investigate the possible synergistic cytotoxic/apoptotic effects of a novel combination, docetaxel and TQ in DU-145 hormone- and drug-refractory prostate cancer cells and their effects on PI3K and ERK signaling pathways. We observed that the combination of docetaxel and TQ resulted in a significant synergistic cytotoxicy and apoptosis as compared to any single agent alone, in a dose-dependent manner. It was found that viability of the combination treated cells was not significantly changed in the presence of LY294002 as compared to inhibitor treated cells. However, in the presence of FR180204, viability of combination treated cells was significantly decreased as compared to inhibitor treated cells. In conclusion, cytotoxic effect of the docetaxel and TQ combination is correlated with the block of the PI3K/Akt signaling pathway in DU-145 cells. Therefore, this combination strategy may be an alternative approach for the challenging era of daily oncologic practice. Also, the combination of docetaxel and TQ might allow a reduction in docetaxel doses and diminish adverse effects of docetaxel while maintaining the therapeutic effect in patients with CRPC.
dc.identifier.issn1699-048X
dc.identifier.other1699-3055
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/9502
dc.language.isoEnglish
dc.publisherSPRINGER INTERNATIONAL PUBLISHING AG
dc.subjectNEUROENDOCRINE DIFFERENTIATION
dc.subjectDOWN-REGULATION
dc.subjectGROWTH
dc.subjectMEN
dc.subjectCHEMOTHERAPY
dc.subjectPREDNISONE
dc.subjectTHERAPY
dc.subjectPLACEBO
dc.subjectPHASE-3
dc.subjectKINASE
dc.titleNovel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu